alexion pharmaceuticals pipeline
An archived version of the remarks will also be available through the Company’s website for a limited time following the conference. Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will … This website is intended only for residents of the United States. We have completed a Phase 1 single ascending dose (“SAD”) study and the results were published in the Journal of Clinical Pharmacology in January 2019. Eloxx Pharmaceuticals Pipeline. – Data highlight long-term and real-world efficacy of SOLIRIS ® (eculizumab) in patients living with rare neurologic complement-mediated disorders, including neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG) –. Alexion Pharmaceuticals is a global leader in the treatment of rare diseases. At only three months old, Evie's parents were told that her case was severe and that there were no approved or effective treatment options. A theme runs through the updates: In each case, Alexion bolstered its early-stage pipeline … When it comes to the pipeline, the immediate goal is to develop seven potential top franchises — expanding the presence in Hematology, Nephrology, Metabolics, Neurology, and Acute Care — while also venturing into … Das Unternehmen ist auf Orphan-Arzneimittel zur Behandlung von seltenen und sehr seltenen Krankheiten spezialisiert. Alexion has 18 planned clinical development programs in 2020 and has ten potential product launches by 2023, in addition to other programs through the acquisition of Achillion Pharmaceuticals, Portola Pharmaceuticals and the minority interest in … Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and … Specialty drugs in the United States - Wikipedia Ludwig Norbert Michel Hantson (born August 1962) is a Belgium businessman, the CEO of Alexion Pharmaceuticals since March 2017. the product pipeline. More details will be available at http://ir.alexion.com leading up to the event. PHASE II. BOSTON--(BUSINESS WIRE)--Sep. 14, 2020-- Filing of certain prospectuses and communications in connection with business combination transactions. CEO Message. Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Feb. 17, 2020 3:43 PM ET. Alexion wurde 1992 unter anderem von Leonard Bell gegründet, einem Professor für Innere Medizin und Pathologie an der Yale University. COMPLETE. PHASE I SAD/MAD. Married with a newborn son, Ruthie was scared to learn that PNH was a life-threatening illness that at the time had no approved treatment. Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition BOSTON -- (BUSINESS WIRE)--Jan. 30, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019. We’re building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology, nephrology, neurology, metabolics, and cardiology. The company continues to expand into additional therapeutic areas as it builds seven rare disease franchises across hematology, nephrology, metabolics, neurology, cardiology, ophthalmology and acute care, which have the potential to deliver more than $10 billion in future peak sales. I believe Alexion Pharmaceuticals is a high growth biopharmaceutical capable of delivering above-average future growth based on a robust pipeline of pending new drugs. 2, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Alexion’s share loses more than 5% to $99.51. Alexion Pharmaceuticals sees continued growth after a solid 2018. Advancing Our Pipeline Every Day We’re building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology, nephrology, neurology, metabolics, and cardiology. ALXN reached a high price of $208.83 back in July 2015. View HTML. Mealy MA, Boscoe A, Caro J, Levy M. Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. Alexion Pharmaceuticals today announced a $930 million takeover of Achillion Pharmaceuticals to expand its research pipeline targeting rare immunological disorders. Alexion projects steady growth and broad pipeline progress. With a focus on devastating and rare diseases, each endeavor is urgent and every day counts. Open Menu. Patent Issues Lead to Diversification. Make a difference for families like Tristan's. Is Alexion Pharmaceuticals a Buy? Despite having a constant struggle with symptoms, Roberta revisited her dreams and put herself through nursing school. Alexion Pharmaceuticals Inc. published this content on 29 July 2020 and is solely responsible for the information contained therein. Internal Research & Discovery. This is in sharp contrast to its trading at approximately 11 times book value in 2013 and 2014, which is referenced … Given its current valuation, I believe that makes it a good investment for anyone with a long-term strategy. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. Alexion completed two acquisitions this year (2020) to add to its commercial portfolio and pipeline. Neurology Reviews. Sign up for your 14-day free trial to FAST Graphs: Secure Your Future Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare and devastating diseases through the discovery, development and commercialization of … Alexion Pharmaceuticals Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. New Haven, CT: Alexion Pharmaceuticals, Inc; 2015. Alexion's leading expertise in complement biology will accelerate AstraZeneca's growing presence in immunology. Post merger, the companies indicated that AstraZeneca plans to work closely with Alexion's R&D team to build upon and expand Alexion's current pipeline of 11 molecules, which have been studied in greater than 20 clinical development programs across a wide spectrum of rare diseases. An audio webcast of the presentation will be available live. View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005428/en/, Investors Jefferies’ Eun Yang, though, said the price is “healthy” for Alexion, especially as competition looms for its C5 franchise and a diversified pipeline has yet to materialize. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Alexion Pharmaceuticals Supporting its near-term pipeline, Alexion is continuing to relentlessly pursue innovation and has an unwavering focus on research that will develop solutions to address patient needs. The deal was one of several pipeline updates Alexion made in connection to its investor day. Chris StevoHead of Investor Relations 2017;(suppl):S1-S4. See insights on Alexion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. 425. A sale to a larger buyer that already has an interest in rare disease therapies, and the scale to invest in Alexion’s diversified pipeline, could make sense. The company is also involved in immune system research related to autoimmune diseases. Financial Highlights. Source: The Company Website. The company is also involved in immune system research related to autoimmune diseases. Alexion has operations in Sweden to serve patients locally. Megan GoulartExecutive Director, Corporate Communications In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company… In June (June 2020), Alexion completed its $1.4-billion acquisition of Portola Pharmaceuticals, a South San Francisco-based commercial-stage biopharmaceutical company focused on rare diseases. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). 2019 Business Highlights. Alexion Pharmaceuticals ist ein biopharmazeutisches Unternehmen mit Sitz in Boston. Neuromyelitis optica spectrum disorders: critical role of complement-dependent cytotoxicity. View HTML. Alexion's pipeline, which currently contains 16 different trials, can be split into 2 categories: Trials to expand the use of Soliris, and trials of new compounds. 0001140361-21-008205.pdf. Synageva BioPharma’s drug Kanuma (sebelipase alfa) is used for the treatment of … AstraZeneca, with Alexion's R&D team, will work to build on Alexion's pipeline of 11 molecules across more than 20 clinical-development programmes across the spectrum of indications, in rare diseases and beyond. Tristan's parents experienced a whirlwind of emotions and fear after learning their 5-year-old son had such a rare and serious disease. Alexion Pharmaceuticals: Price-To-Book Value Suggest Undervaluation Alexion ended 2019 with the stock price trading at 2.12 times book value. Source: Alexion Pharmaceuticals, Inc. News Provided by Acquire Media Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare disorders. As a father of two young children, Donnan recalls being afraid of what the future would hold prior to his diagnosis. Patient Experience. AstraZeneca to Acquire Alexion for US$ 39 Billion to Grow Immunology Pipeline 2020-12-12 2020-12-13 - by GeneOnline - Leave a Comment O n December 12th, British pharma giant AstraZeneca announced that it has entered into a definitive agreement to acquire Boston-based Alexion Pharmaceuticals Inc., for a deal worth US$ 39 billion ($175 per share), paying a 45% premium on the … Source: Alexion Pharmaceuticals, Inc. and Dicerna Pharmaceuticals, Inc. Alexion Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications or Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, Investor Relations or Dicerna Pharmaceuticals Investors Rx Communications Group Paula Schwartz, 917-322-2216 Alexion to Discuss Key Pipeline Programs at Virtual Investor Day BOSTON --(BUSINESS WIRE)--Sep. 14, 2020-- Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October 6th, 2020 from 8:00 a.m. to 12:00 p.m. Source: Alexion Pharmaceuticals, Inc. and Achillion Pharmaceuticals, Inc. Alexion: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, Investor Relations Achillion: Media Susanne Heinzinger, 215-709-3032 Senior VP, Corporate Communications Investors 1. Review the pipeline and the status of clinical studies investigating APL-2 (pegcetacoplan) & APL-9 as a treatment for autoimmune and inflammatory diseases, including geographic atrophy (GA), paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), and complement dependent nephropathies (CDN) LEARN MORE ABOUT ELX-02 PHASE I SAD/MAD . Mar 11, 2021. Alexion and Zealand Pharma have teamed up to develop peptide therapies for complement-mediated diseases. It employs around 2,400 people worldwide. PHASE III. ALEXION PHARMACEUTICALS (ALXN) Price Target: Dominance of Ultomiris, strong and diverse pipeline Pharmaceuticals Inc”, “Alexion Pharmaceuticals”, “Alexion”, or “ALXN” has been We view that Ultomiris will be the leader in the next decade for Paroxysmal SHAHUL HAMEED Shoaib shoaibs.hameed@my.cityu.edu.hk transactions. Groundbreaking innovation, life-saving therapies and a promising pipeline, all driven by a team with a shared sense of purpose and dedication — that’s Alexion. With a strong grip on its target markets and a promising pipeline, this company should continue to grow. Alexion Pharmaceuticals: Pipeline Diversification Outweighs The Patent Uncertainty. BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Pipeline & Acquisitions. Learn about Alexion’s rare disease pipeline in hematology, nephrology, neurology, metabolics, and cardiology. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). Alexion Pharmaceuticals has 3,082 employees across 23 locations and $6.07 B in annual revenue in FY 2020. Because of the confidence in its commercial platform, multiple launches in the coming years and a renewed pipeline, Alexion recently announced a new capital allocation strategy that will return value to shareholders, including a commitment to dedicate at least one third of annual free cash flow to share repurchases from 2021 through 2023, for what is expected to be a total of at least $3 billion in stock … By 2010 Alexion Pharmaceuticals's Soliris, was considered to be the most expensive drug in the world. ET. A Deep Pipeline of XmAb Antibody Drug Candidates. Alexion Pharmaceuticals has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. AstraZeneca stock has the potential to push above $61 per share, aided in part by the drug maker's pending buyout of Alexion, says Jefferies. Alexion Pharmaceuticals has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment. PHASE I. When Alexion bid for Portola Pharmaceuticals, Inc. in early May, adding a premium … It employs around 2,400 people worldwide. Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October 6th, 2020 from 8:00 a.m. to 12:00 p.m. |. In select countries, third-party companies manage our local commercial operations. Filing of certain prospectuses and communications in connection with business combination transactions. Distributed by Public, unedited and … When Albie was born, his mom, Charlotte, said that he was “absolutely fine. Partnerships
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) is getting insufficient credit from investors for its development pipeline, an analyst said Wednesday. Alexion Pharmaceuticals: Pipeline Diversification Outweighs The Patent Uncertainty. 2011 übernahm Alexion Taligen Therapeutics (Cambridge, Massachusetts) und gründete die Translational Medicine Group, um neue Produktkandidaten schneller in die klinische Prüfung bringen zu können. Int J MS Care. Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. IND ENABLING. (857) 338-9309, Media Alexion’s pipeline now includes more than 20 development programs – up from four at the end of 2017 – with the potential for 10 promising launches by 2023. Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | 2019 Annual Report | Our Pipeline. (857) 338-8634, We use cookies to give you the best online experience. Management will highlight continued strategic advancement, including key pipeline opportunities and drivers of future growth. Geschichte. - Lisa: Living with … BOSTON -- (BUSINESS WIRE)--Jul. Alexion wird an der NASDAQ gehandelt und ist im NASDAQ-100 gelistet. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Sites. Alexion said that it has entered a definitive agreement to acquire the US biotech company Achillion Pharmaceuticals. We are working to expand into new complement indications and strengthen our clinical-stage pipeline through internal and external development opportunities in our core areas. Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 BOSTON -- (BUSINESS WIRE)--Feb. 4, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. The company has added quite a bit to the pipeline last year, but reliance risks on Soliris remains. AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. 2019;21(3):129-134. ELX-02. 1. Wingerchuk DM. We support clinically and scientifically sound independent research to generate evidence and ultimately contribute to advancing patient care. BOSTON--(BUSINESS WIRE)--Sep. 14, 2020-- Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October 6th, 2020 from 8:00 a.m. to 12:00 p.m. ET.Management will highlight continued strategic advancement, including key pipeline … Alexion Pharmaceuticals, Inc. Media Irving Adler, 203-271-8210 Vice President, Corporate Communications or Kim Diamond, 203-439-9600 Executive Director, Corporate Communications or Investors Elena Ridloff, CFA, 203-699-7722 Executive Director, Investor Relations. We continue to evolve into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives. |. XmAb antibodies and cytokines are being developed by Xencor and our partners in 20 different clinical programs for the treatment of life-threatening and debilitating diseases. By using our website, you agree to our use of cookies in accordance with our, Alexion to Discuss Key Pipeline Programs at Virtual Investor Day. The company is also involved in immune system research related to autoimmune diseases. Home. In select countries, third-party companies manage our local commercial operations. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced continued progression of the company’s LEAD-EXPAND-DIVERSIFY value-creation strategy and will highlight strategic advancements at today’s Virtual Investor Day. As we develop and deliver life-changing medicines, we are also leveraging a proprietary bioinformatics platform to strengthen our understanding of rare diseases and provide insights into their epidemiology. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). 0001104659-21-035337.pdf. ET . Alexion has a strong pipeline. Everything was fine for about two weeks.”. © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20200914005428/en/. Working at Alexion is an experience like no other. PHARMACEUTICALS MALHOTRA Samya smalhotra6 … Alexion Pharmaceuticals: No Competition, A Solid Pipeline And Takeover Fever Feb. 06, 2012 1:20 PM ET Alexion Pharmaceuticals, Inc. (ALXN) REGN 1 Comment Helix Investment Research Supporting its near-term pipeline, Alexion is continuing to relentlessly pursue innovation and has an unwavering focus on research that will develop solutions to address patient needs. – Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases – BOSTON -- (BUSINESS WIRE)--Jan. 28, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. I believe Alexion Pharmaceuticals is a high-growth biopharmaceutical capable of delivering above-average future growth based on a robust pipeline of pending new drugs. Mar 2, 2021. Internal Research & Discovery. Through our Externally Sponsored Research (ESR) program, we receive, review and respond to unsolicited proposals from external sponsors requesting funding.